Tradestie Institutional Equity Comparison Engine

CLYM vs NBP โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CLYM Overall Edge

CLYM Captures Institutional Edge (2โ€“1 Pillars ยท 3โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Climb Bio, Inc. Common Stock (CLYM) driven by superior Growth & Margin, Momentum & Technical while NBP counters with relative strength in Valuation. Fundamentally, CLYM trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus NBP at 2.7x Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, CLYM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against NBP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner NBP
CLYM N/M vs NBP 2.7x Fwd P/E
Growth & Margin Winner CLYM
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner CLYM
1Y +434.8% vs -81.0% ยท 52W Pos 50% vs 0%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
CLYM NASDAQ
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$10.00
-3.47% 1D
Market Cap $638.5M
1M Return +1.83%
1Y Return +434.76%
Forward P/E N/M
Unified AI Score
41.9 / 100 SELL
Tech 38.0 Fund 42.0 Flow 50.0 Mom 54.0
NBP US Equity
NBP
Institutional Equity
$0.79
-6.66% 1D
Market Cap $96.3M
1M Return -37.04%
1Y Return -80.98%
Forward P/E 2.7x
Unified AI Score
51.9 / 100 HOLD
Tech 60.0 Fund 50.0 Flow 50.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CLYM +434.76% NBP -80.98% Spread: +515.74 pp (CLYM Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CLYM TTM Op. Margin: 0.0% NBP TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLYM vs NBP. Trailing 12-month operating profitability (CLYM 0.0% vs NBP 0.0%) and valuation multiples (CLYM N/M vs NBP 2.7x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CLYM (3) vs NBP (4)
Institutional Metric CLYM NBP Criterion Row Winner
Market Capitalization Scale $638.5M $96.3M Larger Scale CLYM
Trailing P/E Ratio Valuation N/M 2.7x Lower Multiple NBP
Forward P/E Ratio Valuation N/M 2.7x Lower Multiple NBP
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -29.3% -59.1% Higher ROE CLYM
52-Week Range Position Momentum 50% ($2โ€“$18) 0% ($1โ€“$5) Stronger Trend CLYM
Beta / 30D Volatility Risk Regime 1.50ฮฒ ยท 114% Vol 1.66ฮฒ ยท 81% Vol Lower Realized Risk NBP
Unified Institutional Score Composite Signal 41.9 / 100 (SELL) 51.9 / 100 (HOLD) Higher Composite NBP

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CLYM vs NBP Buy Guide
CLYM UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CLYM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
NBP UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live NBP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CLYM nor NBP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.